Advances in Plasma Oncology toward Clinical Translation

Dear Colleagues,

In the past decade, cold atmospheric plasmas (CAPs) have been under investigation for their potential for cancer treatment, thus opening the young, multidisciplinary field of plasma oncology. CAPs are tunable sources for the production and delivery of reactive oxygen and nitrogen species (RONS), which positions them as a unique tool to study intracellular redox pathways and for development as a novel redox therapy.

As new research tools and more sophisticated 3D in vitro cancer models are emerging, the role of the tumor microenvironment is attracting greater attention among plasma-cancer researchers. Strategies for combination therapy, e.g., immunotherapy, are also of great importance and are currently under development. There is a clear need for a better understanding of the underlying mechanisms, but at the same time, we should start thinking about the move toward clinical translation of this promising technology.

In this Special Issue, we will publish original research papers that provide fundamental understanding into the mechanisms of CAPs in cancer treatment, ranging from computer modeling to in vitro and in vivo experiments and clinical trials. New insights should preferably be considered and discussed in the context of clinical translation or application.

Dr. Annemie Bogaerts
Dr. Katharina Stapelmann
Dr. Abraham Lin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.